{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.270","statisticalMethod":"t-test, 2 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.82","value":"1.04"},{"groupId":"OG001","spread":"9.38","value":"-0.71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"description":"The overall HRQL was measured by the change in Functional Assessment of Cancer Therapy - General (FACT-G) from baseline to 6 months after randomization. The FACT-G is a 27-item assessment used to measure HRQL, specifically, physical, functional, social and emotional well-being. The total score ranges from 0 to 108, with higher scores indicating better HRQL.","dispersionType":"Standard Deviation","groups":[{"description":"Following induction rituximab, patients who were randomized to this arm received rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months.","id":"OG000","title":"Arm A: Rituximab Retreatment"},{"description":"Following induction rituximab, patients who were randomized to this arm received a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity.","id":"OG001","title":"Arm B: Rituximab Scheduled"}],"paramType":"MEAN","populationDescription":"Patients with patient-reported outcomes (PRO) data available.","reportingStatus":"POSTED","timeFrame":"Assessed at baseline and 6 months after randomization.","title":"Overall Health-related Quality of Life (HRQL) at 6 Month After Randomization","type":"SECONDARY","unitOfMeasure":"units on a scale"}